Devolving of statin prescribing to general practitioners for HIV-infected patients receiving antiretroviral therapy

International Journal of STD and AIDS

Volumn 20, Issue 3, 2009, Pages 202-204

  Benn, P D ^a   Miller, R F ^b   Evans, L ^a   Minton, J ^c   Edwards, S G ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Antiretroviral therapy; Drug drug interactions; General practitioners; HIV; Statins

Indexed keywords

ATORVASTATIN; PRAVASTATIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SIMVASTATIN;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CLINICAL PRACTICE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENERAL PRACTITIONER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MEDICATION ERROR; PATIENT CARE; PATIENT SAFETY; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION;

ADULT; AGED; ANTI-RETROVIRAL AGENTS; DRUG INTERACTIONS; DRUG PRESCRIPTIONS; FAMILY PRACTICE; FEMALE; HIV INFECTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEDICATION ERRORS; MIDDLE AGED; POLYPHARMACY; QUALITY OF HEALTH CARE;

EID: 62249164350     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2008.008273     Document Type: Article

References (14)

1. Testing times - HIV and other sexually transmitted infections in the UK: 2007. See http://www.hpa.org.uk/web/HPAwebFile/HPAweb-C/1203496897276 (accessed 20 June 2008)
2. Purdy BD, Raymond AM, Lesar TS. Antiretroviral prescribing errors in hospitalized patients. Ann Pharmacother 2000;34:833-8
3. DeLorenze GN, Follansbee SF, Nguyen DP, et al. Medication error in the care of HIV/AIDS patients: electronic surveillance, confirmation, and adverse events. Med Care 2005;43:III63-68
4. Rastegar DA, Knight AM, Monolakis JS. Antiretroviral medication errors among hospitalized patients with HIV infection. Clin Infect Dis 2006;43:933-8
5. Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2003;289:1107-16
6. El-Sadr WM, Lundgren JD, Neaton JD, et al., Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283 - 96
7. Noor MA, Flint OP, Maa JF, Parker RA. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS 2006;20:1813-21
8. Jones R, Sawleshwarkar S, Michailidis C, et al. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleosidereverse transcriptase inhibitor backbone. HIV Med 2005;6:396-402
9. Friis-Møller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;20;349:1993-2003
10. Friis-Moller N, Reiss P, Sabin CA, et al., DAD study group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723-35
11. Sabin CA, Worm SW, Weber R, et at., D:A:D study group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008;371:1417-26
12. National Institute for Health Clinical Excellence. 2008. Lipid Modification. Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease. See http://www.nice.org.uk/nicemedia/pdf/CG67NICEguideline.pdf (accessed 20 June 2008)
13. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. NIAID AIDS Clinical Trials Group. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 2002;6:569-77
14. Coyne KM, Boffito M, Theobald N, Asboe D. Simvastatin co-prescribed with protease inhibitors despite dangerous drug interactions. Sex Transm Inf 2007;83:498-9